← All trials
NCT02000089
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 6, 2014
- Primary completion
- Oct 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Dec 3, 2013
- Last posted
- Dec 22, 2023
- Enrollment
- 7000
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johns Hopkins UniversityLead sponsor
- ChiRhoClin, Inc.Collaborator
- Johns Hopkins UniversityOverall official - principal investigator
- National Cancer Institute (NCI)Collaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.